Zeta Surgical Inc. has raised $5.2 million in seed funding to improve the accuracy and safety of image-guided surgical procedures through its Zeta neurosurgical navigation platform. Zeta CEO Jose Maria Amich told BioWorld the funding will also advance a non-invasive ultrasound system for imaging the brain and help complete initial clinical studies for its FDA approvals application.
Rather than focus on making one drug at a time, Creyon Bio Inc. is taking its more than $40 million in seed and series A financing to build its platform to understand the genetic roots of disease and then create precision medicines. Creyon is creating datasets to engineer RNA-based and single-stranded oligonucleotide-based medicines (OBMs) in addition to DNA and RNA editing systems. Those datasets are tailored to deliver models that create OBMs that are safe and effective for treating both common diseases and rare diseases.
Astrazeneca plc has announced two significant R&D deals with Scorpion Therapeutics Inc. and Benevolentai Ltd., which it hopes will sharpen its research into cancer, lupus and heart failure. Both of the deals involve artificial intelligence (AI) as a way to increase the probability of success during the clinical development process and reduce the chances of costly trial failures.
Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.
There are many companies using artificial intelligence to aid drug development, with a seemingly overwhelming number of “world firsts” being claimed in this quickly evolving field. After signing a three-year neurology drug development deal with Eli Lilly and Co. worth up to $706 million in July, Verge Genomics is also making waves and just raised $98 million in series B financing to support development of its own AI drug development technology.
PERTH, Australia – Australia attracted international attention in July when a Federal Court ruled that artificial intelligence can be named as the inventor of a patent. In Thaler v. Commissioner of Patents, Federal Court Justice Jonathan Beach ruled that under Australian patent law, inventors don’t necessarily have to be human. The decision challenges the assumption that only human beings can be inventors. Beach did rule, however, that an AI system cannot apply for a patent or receive a patent.
Stereotaxis Corp. reported positive results showing its robotic magnetic navigation (RMN) system significantly reduces the incidence of silent cerebral embolism (SCE) in patients undergoing atrial fibrillation (AF) ablation vs. hand-held catheters. The prospective, multicenter study is believed to be the first to compare AF ablation using RMN with manual control and to highlight the benefit in lowering SCE risk.
The COVID-19 pandemic has pushed India’s pharmaceutical and medical device industries towards the more widespread use of blockchain as part of a significant digital transformation effort underpinned by growing use of the Internet of Things (IoT), machine learning (ML) and the use of artificial intelligence (AI).
The increasing use of artificial intelligence (AI) technologies across all stages of drug development is presenting challenges for regulators across the world.
PERTH, Australia – In a possible world-first decision, an Australian court has ruled that artificial intelligence can be named as the inventor of a patent.
